Clinical Trials Browser

Completed × Lymphoma, Non-Hodgkin × Nivolumab × Clear all

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase 1/2 Completed

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03366272 2025-01-28

NIVEAU

Phase 2/3 Completed

348 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT03310619 2024-04-04

PLATFORM

Phase 1/2 Completed

62 enrolled 41 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Phase 1/2 Completed

140 enrolled 23 charts

CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT02061761 2023-03-24

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Phase 1/2 Completed

106 enrolled 27 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT02038933 2021-10-14

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Phase 2 Completed

121 enrolled 16 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT02973113 2021-07-21

PREVALE

Phase 1 Completed

8 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders

NCT01822509 2021-06-24

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Phase 1 Completed

71 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

RELATIVITY-069

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

NIVEAU

PLATFORM

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

PREVALE

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant